Cushings Syndrome Diagnostics and Therapeutics Market

Cushing’s Syndrome Diagnostics and Therapeutics Market Size

The global Cushing’s syndrome diagnostics and therapeutics market was valued at USD 386.5 million in 2024. The market is expected to grow from USD 422.9 million in 2025 to USD 936.2 million in 2034, at a CAGR of 9.2% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to rising prevalence Cushing’s syndrome, expansion of orphan drug designations and regulatory incentives, and increasing R&D investments in selective cortisol modulators.

Cushing’s syndrome diagnostics and therapeutics solutions are transforming endocrine care by enabling accurate detection and targeted treatment of hypercortisolemia. These innovations offer reduced misdiagnosis, better management of the disease, and enhanced patient outcomes with precision endocrinology. Top providers like Corcept THERAPEUTICS, RECORDATI, NOVARTIS, ESTEVE, and Thermo Fisher SCIENTIFIC offer advanced diagnostic platforms and therapeutic agents that are enabled by biochemical reagents, imaging technologies, and receptor-specific drugs. Their integrated solutions address both pituitary and adrenal forms of the disease, supporting personalized care and long-term disease control.

The market has increased from USD 286.3 million in 2021 and reached USD 348.5 million in 2023, with a historic growth rate of 10.3%. This expansion has been driven by growing awareness of Cushing’s syndrome, improvements in diagnostic accuracy through advanced biochemical and imaging techniques, and the rising adoption of targeted therapies that offer better efficacy and safety profiles.

Traditional treatment options, such as surgery or radiation, while effective in some cases, often come with significant risks and limitations, especially for patients with recurrent or inoperable disease. In recent years, pharmaceutical advancements have introduced a new generation of drugs that specifically target the underlying mechanisms of cortisol overproduction. These include adrenal steroidogenesis inhibitors like osilodrostat and levoketoconazole, which block cortisol synthesis, and glucocorticoid receptor antagonists such as mifepristone and relacorilant, which mitigate the effects of excess cortisol at the receptor level.

These therapies not only offer better disease control but also present fewer side effects and improved tolerability, making them suitable for long-term management. Their availability has expanded treatment options for endocrinologists and improved the quality of life for patients, contributing significantly to market growth and clinical adoption.

Cushing’s syndrome is a rare endocrine disorder caused by prolonged exposure to elevated cortisol levels. It can be endogenous or exogenous. Diagnosis involves biochemical tests and imaging, while treatment includes surgery, radiation, and pharmacological therapies aimed at reducing cortisol production or blocking its effects.

Cushing’s Syndrome Diagnostics and Therapeutics Market Trends

Advancements in diagnostic technologies have emerged as a critical growth driver for the market.

• Recent innovations have significantly improved diagnostic accuracy and reduced delays in detection. Techniques such as late-night salivary cortisol testing, 24-hour urinary free cortisol measurement, and high-sensitivity plasma ACTH assays are now widely adopted, offering non-invasive and reliable screening options. These methods enable clinicians to identify hypercortisolemia earlier, which is essential for timely intervention and better patient outcomes.
  
• In addition to biochemical assays, imaging technologies have advanced considerably. High-resolution MRI and CT scans, combined with functional imaging modalities like PET, allow precise localization of tumors responsible for cortisol overproduction.
  
• Furthermore, the integration of AI-driven diagnostic algorithms and digital health platforms is revolutionizing the diagnostic landscape. These tools analyze complex datasets, predict disease patterns, and assist in differentiating subtypes of Cushing’s syndrome, thereby supporting personalized treatment strategies.
  
• Collectively, these advancements are not only improving clinical decision-making but also expanding the adoption of diagnostic solutions globally, fueling market growth
  

Cushing’s Syndrome Diagnostics and Therapeutics Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on category, the Cushing’s syndrome diagnostics and therapeutics market is segmented into therapeutics and diagnostics. The therapeutics segment accounted for 78.8% of the market in 2024 due to its dominant role in managing Cushing’s syndrome, where pharmacological interventions remain the primary option for patients who are ineligible for surgery or experience recurrence after surgical treatment. The segment is expected to exceed USD 727.4 million by 2034, growing at a CAGR of 9.1% during the forecast period.

On the other hand, the diagnostics segment held a significant market share of 21.2% in 2024, and its growth can be attributed to the increasing adoption of advanced biochemical assays, high-resolution imaging, and AI-driven diagnostic tools that enable earlier detection and accurate differentiation of Cushing’s syndrome subtypes.

• This dominance of the therapeutics segment is further reinforced by the growing adoption of steroidogenesis inhibitors such as osilodrostat, along with glucocorticoid receptor antagonists like mifepristone, which have significantly expanded treatment accessibility and improved clinical outcomes. These drugs offer targeted mechanisms of action, better tolerability, and long-term disease control, making them indispensable in chronic management.
  
• Additionally, the segment’s growth is supported by orphan drug designations, regulatory incentives, and continuous R&D investments that accelerate the development of next-generation therapies. With an increasing focus on personalized medicine and precision endocrinology, therapeutics have become the cornerstone of Cushing’s syndrome care, driving revenue share and market leadership within the overall diagnostics and therapeutics landscape.
  

Based on disease type, the Cushing’s syndrome diagnostics and therapeutics market is segmented into exogenous Cushing's syndrome and endogenous Cushing's syndrome. The exogenous Cushing's syndrome segment continues to dominate, accounting for a majority market share valued at USD 299.5 million in 2024.

• This dominance is primarily driven by the high incidence of corticosteroid overuse in chronic conditions such as asthma, rheumatoid arthritis, and autoimmune disorders. Its prevalence, coupled with the widespread prescription of glucocorticoids, drives consistent demand for diagnostic monitoring and therapeutic interventions, reinforcing its leading position in the overall market.
  
• The endogenous Cushing's syndrome segment held a revenue of USD 87 million in 2024, with projections indicating a steady expansion at 8.6% CAGR from 2025 to 2034. This growth is fueled by increasing awareness and improved diagnostic capabilities for differentiating endogenous causes, such as pituitary and adrenal tumors, along with the rising adoption of advanced imaging and biochemical assays. Additionally, the development of targeted therapies and orphan drug incentives for rare endocrine disorders is driving greater treatment accessibility and clinical adoption in this segment.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the Cushing’s syndrome diagnostics and therapeutics market is segmented into hospitals & clinics, homecare settings, diagnostic centers, and other end users. The hospitals & clinics segment accounted for USD 192.1 million in 2024 and is expected to grow at a 9% CAGR from 2025 to 2034. 

• This growth is driven by the rising number of surgical interventions for Cushing’s syndrome, greater adoption of advanced diagnostic imaging and biochemical testing, and the availability of specialized endocrinology units offering comprehensive care. Moreover, these facilities serve as the primary point of access for complex cases requiring multidisciplinary management, further strengthening their market share and reinforcing their growth trajectory.
  
• The homecare settings segment accounted for USD 109.8 million in 2024 and is expected to grow at a 9.5% CAGR from 2025 to 2034. This growth is supported by the increasing preference for outpatient procedures that offer cost efficiency and reduced hospital stays.
  
• The diagnostic centers segment accounted for USD 61.7 million in 2024 and is expected to grow at a 9.9% CAGR from 2025 to 2034. This growth is driven by the rising demand for specialized endocrine testing, including advanced biochemical assays and imaging services, as well as the increasing adoption of AI-powered diagnostic platforms that enable accurate and early detection of Cushing’s syndrome. Additionally, the trend toward outsourcing complex diagnostic procedures to dedicated centers for cost efficiency and expertise is further fueling segment expansion.
  
• The other end users segment is expected to grow at a substantial pace during the period from 2025 to 2034 at a CAGR of 8.2%. This segment includes research institutes, academic centers, and ambulatory surgical centers. Growth in this category is driven by increasing R&D collaborations, rising investments in rare disease studies, and the need for advanced diagnostic and therapeutic solutions to support innovation and regulatory approvals.
  

Looking for region specific data?

Download Free PDF

North America Cushing’s Syndrome Diagnostics and Therapeutics Market

North America dominated the market with the highest market share of 41.7% in 2024.

• The U.S. Cushing’s syndrome diagnostics and therapeutics market was valued at USD 117 million and USD 127.7 million in 2021 and 2022, respectively. The market size reached USD 153.7 million in 2024, growing from USD 139.9 million in 2023, and is anticipated to grow at a CAGR of 8.2% between 2025 and 2034.
  
• The region benefits from favorable regulatory frameworks, including orphan drug designations and reimbursement policies, which accelerate the availability of innovative therapies. The presence of leading pharmaceutical companies such as Corcept Therapeutics and Novartis further strengthens the market, supported by robust clinical research and commercialization strategies. The increasing prevalence of endocrine disorders and associated comorbidities like diabetes and obesity continues to expand the patient pool, fueling demand for both diagnostic and therapeutic solutions.
  
• Additionally, technological advancements, including AI-powered diagnostic tools and minimally invasive surgical techniques, are enhancing early detection and improving patient outcomes. The growing trend toward personalized medicine and telehealth platforms is also reshaping care delivery, making treatment more accessible across urban and rural areas.
  

Europe Cushing’s Syndrome Diagnostics and Therapeutics Market

Europe market accounted for USD 107.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.

• Countries such as Germany, the UK, and France lead in implementing precision endocrinology practices, supported by strong clinical research networks and government-backed rare disease programs.
  
• The region’s emphasis on early diagnosis through biochemical assays and imaging techniques is improving detection rates, while the availability of novel drugs like osilodrostat and pasireotide is expanding therapeutic options for patients who are ineligible for surgery.
  
• Market growth in Europe is further supported by favorable regulatory incentives, including orphan drug status and accelerated approval pathways, which encourage pharmaceutical innovation.
  

Asia Pacific Cushing’s Syndrome Diagnostics and Therapeutics Market

The Asia Pacific market is anticipated to grow at a CAGR of 10.3% during the analysis timeframe.

• Asia-Pacific is the fastest-growing regional market, driven by rising healthcare investments, improving diagnostic infrastructure, and growing awareness of endocrine disorders.
  
• Countries like China, India, and Japan are witnessing increased adoption of advanced biochemical testing and imaging technologies, supported by government initiatives to strengthen rare disease management.
  
• The region’s large population base and rising incidence of obesity and diabetes, which are often associated with Cushing’s syndrome, create significant opportunities for diagnostics and therapeutics providers.
  
• Pharmaceutical companies are increasingly targeting Asia-Pacific for clinical trials and market expansion, leveraging cost advantages and improving regulatory frameworks.
  

Latin America Cushing’s Syndrome Diagnostics and Therapeutics Market

The Latin America market is experiencing robust growth over the analysis timeframe.

• Countries like Brazil and Mexico are leading the regional adoption of advanced diagnostic techniques, including salivary cortisol testing and imaging modalities.
  
• The increasing prevalence of chronic conditions requiring corticosteroid therapy, coupled with efforts to enhance early detection, is driving demand for specialized diagnostic services.
  
• Therapeutic adoption is gradually increasing, with multinational pharmaceutical companies expanding their presence through partnerships and distribution agreements.
  

Middle East & Africa Cushing’s Syndrome Diagnostics and Therapeutics Market

The Middle East & Africa (MEA) market is experiencing notable growth over the analysis timeframe.

• Countries such as Saudi Arabia, UAE, and South Africa are witnessing greater adoption of advanced diagnostic tools, including biochemical assays and diagnostic imaging services. Government initiatives to improve rare disease management and the growing presence of international pharmaceutical companies are further supporting market development.
  

Cushing’s Syndrome Diagnostics and Therapeutics Market Share

Leading industry players such as Corcept THERAPEUTICS, RECORDAT, NOVARTIS, ESTEVE, Thermo Fisher SCIENTIFIC collectively hold a dominant share of the global market, accounting for nearly 35% of total market. These companies maintain leadership through strong portfolios of targeted therapies, including steroidogenesis inhibitors, glucocorticoid receptor antagonists, and pituitary-directed drugs, supported by extensive clinical validation and regulatory approvals.

Their competitive edge is reinforced by orphan drug designations, global distribution networks, and continuous investment in R&D to develop next-generation selective cortisol modulators. Strategic collaborations with research institutions and healthcare providers further strengthen their market position, ensuring broad adoption across hospitals and specialty centers.

Meanwhile, emerging players are carving out niches by focusing on innovative pipeline drugs, cost-effective treatment solutions, and patient-centric care models. These companies leverage partnerships with academic institutions and digital health platforms to accelerate clinical trials and expand access in underserved regions, particularly in the Asia-Pacific and Latin America. Their emphasis on affordability, precision medicine, and differentiated mechanisms of action positions them as strong contenders in a market increasingly driven by innovation and personalized therapy.

Cushing’s Syndrome Diagnostics and Therapeutics Market Companies

A few of the prominent players operating in the Cushing’s syndrome diagnostics and therapeutics industry include:

• ALPCO
• Corcept THERAPEUTICS
• DiaMetra
• ESTEVE
• labcorp
• Lucichem Pharma
• NOVARTIS
• Pfizer
• RECORDATI
• SALIMETRICS
• teva
• Thermo Fisher SCIENTIFIC
  
• Corcept THERAPEUTICS

Corcept Therapeutics is a leader in cortisol modulation therapies, with a USP centered on its expertise in developing selective glucocorticoid receptor antagonists. Its flagship product Korlym (mifepristone), and next-generation candidate, relacorilant, offer targeted solutions for hypercortisolism, improving metabolic and cardiovascular outcomes. Corcept’s strength lies in its deep clinical research, orphan drug designations, and commitment to precision endocrinology, making it a benchmark in medical management of Cushing’s syndrome.

• RECORDATI

Recordati stands out as a global rare disease specialist, with a USP focused on its advanced steroidogenesis inhibitor Isturisa (osilodrostat) for endogenous Cushing’s syndrome. The company combines strong regulatory expertise, comprehensive clinical programs, and global distribution capabilities to deliver effective therapies for patients who are ineligible for surgery. Recordati’s emphasis on rare endocrine disorders and its ability to scale across multiple geographies reinforce its leadership in niche therapeutic markets.

• NOVARTIS

Novartis is a pharmaceutical giant with a USP rooted in its diversified portfolio and innovation in pituitary-targeted therapies, including Signifor (pasireotide) for Cushing’s disease. The company leverages cutting-edge research, global clinical networks, and AI-driven drug development to advance precision medicine. Novartis’ strong regulatory track record, extensive patient support programs, and commitment to rare disease treatment position it as a dominant force in the Cushing’s syndrome therapeutics landscape.

Cushing’s Syndrome Diagnostics and Therapeutics Industry News:

• In April 2025, Recordati announced that the FDA granted an expanded indication for Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome. This may help the company strengthen its leadership in rare endocrine disorders and broaden its therapeutic reach to patients who are ineligible for surgery or have persistent disease.
  
• In September 2024, Esteve completed the acquisition of HRA Pharma Rare Diseases, adding a portfolio of specialized treatments for endocrine disorders, including Cushing’s syndrome. This helped the company enhance its presence in the rare disease segment and accelerate its growth strategy focused on high-value, niche therapeutic areas.
  

The Cushing’s syndrome diagnostics and therapeutics market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Category

• Therapeutics
  • Surgery
    • Transsphenoidal surgery
    • Adrenalectomy
  • Drugs
    • Pituitary-directed drugs
    • Adrenal steroidogenesis inhibitors
    • Glucocorticoid receptor antagonists
    • Other drugs
  • Radiation Therapy
• Diagnostics
  • Inferior petrosal sinus sampling
  • Late-night salivary cortisol test
  • 24-hour urine & blood cortisol panels
  • Imaging tests
  • Other diagnostic tests

Market, By Disease Type

• Exogenous Cushing's syndrome
• Endogenous Cushing's syndrome

Market, By End Use

• Hospitals & clinics
• Homecare settings
• Diagnostic centers
• Other End Use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE